Download PDF
TumorDiagnostik & Therapie 2017; 38(09): 558-561
DOI: 10.1055/s-0043-119228
Schwerpunkt Prostatakarzinom
© Georg Thieme Verlag KG Stuttgart · New York

Revolution in der bildgebenden Diagnostik des Prostatakarzinoms: die PSMA-Liganden PET

Isabel Rauscher
,
Matthias Eiber
,
Tobias Maurer
Further Information

Publication History

Publication Date:
07 November 2017 (online)

Also available at
    Permissions and Reprints

Die PET mit Liganden des prostataspezifischen Membranantigens (PSMA-Liganden PET) ist konventionellen Verfahren in Spezifität und Sensitivität überlegen. Dadurch hat die neue Technologie auch Einzug in die aktuelle S3-Leitlinie gehalten.
 

  • Literatur

  • 1 Ahmed HU, El-Shater BosailyA, Brown LC. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017; 389: 815-822
    CrossrefPubMedGoogle Scholar
  • 2 Eder M, Schafer M, Bauder-Wust U. et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012; 23: 688-697
    CrossrefPubMedGoogle Scholar
  • 3 Eiber M, Weirich G, Holzapfel K. et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Eur Urol 2016; 70: 829-836
    CrossrefPubMedGoogle Scholar
  • 4 Maurer T, Gschwend JE, Rauscher I. et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomografy Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol 2016; 195: 1436-1443
    CrossrefPubMedGoogle Scholar
  • 5 Jilg CA, Drendel V, Rischke HC. et al. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer. Theranostics 2017; 7: 1770-1780
    CrossrefPubMedGoogle Scholar
  • 6 Pyka T, Okamoto S, Dahlbender M. et al. Comparison of bone scintigrafy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 2114-2121
    CrossrefPubMedGoogle Scholar
  • 7 Afshar-Oromieh A, Avtzi E, Giesel FL. et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209
    CrossrefPubMedGoogle Scholar
  • 8 Eiber M, Maurer T, Souvatzoglou M. et al. Evaluation of Hybrid (68)Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2015; 56: 668-674
    CrossrefPubMedGoogle Scholar
  • 9 Afshar-Oromieh A, Holland-Letz T, Giesel FL. et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 2017; 44: 1258-1268
    CrossrefPubMedGoogle Scholar
  • 10 Rauscher I, Maurer T, Beer AJ. et al. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. J Nucl Med 2016; 57: 1713-1719
    CrossrefPubMedGoogle Scholar
  • 11 Krohn T, Verburg FA, Pufe T. et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging 2015; 42: 210-214
    CrossrefPubMedGoogle Scholar
  • 12 Giesel FL, Hadaschik B, Cardinale J. et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 2017; 44: 678-688
    CrossrefPubMedGoogle Scholar